Log in with your email address username.


[Comment] Treatment for severe eosinophilic asthma—consistent effect of anti-interleukin-5 antibodies?

A major advance in the development of a precision medicine approach for the treatment of severe asthma has been the elucidation of an eosinophilic driven phenotype that responds well to a monoclonal antibody directed against interleukin 5. Recognition that an increased blood eosinophil level in asthma is directly related to future exacerbations, decline in lung function, and absence of asthma control1,2 has led to use of eosinophils as one of the first, readily available biomarkers in the treatment of asthma.